Evidence for a decrease in cardiovascular risk factors following recombinant growth hormone administration in abstinent anabolic-androgenic steroid users

Evidence for a decrease in cardiovascular risk factors following recombinant growth hormone administration in abstinent anabolic-androgenic steroid users / Michael R. Graham, Julien S. Baker, Peter Evans, Andrew Kicman, David Cowan, David Hullin, Bruce Davies. - (Growth Hormone & IGF Research 17 (2007) 3 (June); p. 201-209)

  • PMID: 17324600
  • DOI: 10.1016/j.ghir.2007.01.010


Abstract

Objectives: To determine whether six days recombinant human growth hormone (rhGH) in an abstinent anabolic-androgenic steroid (AAS) group had any cardiovascular and biochemical effects compared with a control group.

Methods: Male subjects (n=48) were randomly divided, using a single blind procedure into two groups: (1) control group (C) n=24, mean+/-SD, age 32+/-11 years; height 1.8+/-0.06m; (2) rhGH using group (0.058IUkg(-1)day(-1)) (GH) n=24, mean+/-SD, age 32+/-9 years; height 1.8+/-0.07m. Physiological responses, anthropometry, arterial pulse wave velocity (APWV), blood pressure (BP), heart rate (HR), peak oxygen uptake (VO(2) peak) and biochemical indices were investigated.

Results: Body mass index, fat-free mass index and VO(2) peak significantly increased while body fat significantly decreased within GH (all P<0.017). Insulin like growth factor-I significantly increased within GH (P<0.017) and compared with C (P<0.05). Serum sodium significantly increased (P<0.017) and serum homocysteine, high sensitivity C-reactive protein, thyroid stimulating hormone and tetra-iodothyronine (T(4)), significantly decreased within GH (all P<0.017). T(4) significantly decreased compared with C (P<0.05). Arterial pulse wave velocity, peak and recovery systolic and diastolic BP, significantly decreased compared with C (P<0.05). Resting HR and rate pressure product (RPP) significantly increased compared with C (P<0.05).

Conclusion: The findings of this study suggest that short term use of rhGH may have beneficial effects on endothelial function and specific inflammatory markers of cardiovascular disease in abstinent AAS users, but may have an adverse effect on the cardiovascular system, as evidenced by the increase in resting RPP.

Original document

Parameters

Science
Study
Date
26 February 2007
People
Baker, Julien S.
Cowan, David A.
Davies, Bruce
Evans, Peter
Graham, Michael R.
Hullin, David
Kicman, Andrew T.
Country
United Kingdom
Language
English
Other organisations
King's College London (KCL)
Royal Gwent Hospital
University of Glamorgan
Laboratories
London, United Kingdom: Drug Control Centre
Doping classes
S2. Peptide Hormones, Growth Factors
Substances
Growth hormone (GH)
Medical terms
Cardiovascular diseases
Health effects
Document category
Scientific article
Document type
Pdf file
Date generated
29 June 2020
Date of last modification
5 August 2020
Category
  • Legal Source
  • Education
  • Science
  • Statistics
  • History
Country & language
  • Country
  • Language
Other filters
  • ADRV
  • Legal Terms
  • Sport/IFs
  • Other organisations
  • Laboratories
  • Analytical aspects
  • Doping classes
  • Substances
  • Medical terms
  • Various
  • Version
  • Document category
  • Document type
Publication period
Origin